Abstract: In one aspect, the present invention relates to a pharmaceutical unit dosage composition comprising an antibody of isotype immunoglobulin E (IgE), wherein the composition comprises less than 50 mg of the IgE antibody.

Abstract: The present invention relates to magnetic nanoparticles based on iron oxide having cubic shape, suitably functionalized for the release of targeting chemotherapeutic agents, i.e. selectively in the tumors being treated The invention also relates to the pharmaceutical compositions having such nanoparticles and to their use in combined oncological therapies of hyperthermia and chemotherapy, useful in particular in the treatment of ovarian tumors.

Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

Abstract: The present invention relates to magnetic nanoparticles based on iron oxide having cubic shape, suitably functionalized for the release of targeting chemotherapeutic agents, i.e. selectively in the tumors being treated The invention also relates to the pharmaceutical compositions having such nanoparticles and to their use in combined oncological therapies of hyperthermia and chemotherapy, useful in particular in the treatment of ovarian tumors.

Abstract: The present invention concerns the field of cancer immunotherapy, and in particular drugs with low toxicity which can overcome drug-resistance. The present invention concerns novel bispecific antibodies which have the capability of binding both the TRAIL tumor associated antigen and the T lymphocyte CD3. The invention further relates to compositions comprising the bispecific antibodies and a labelling agent, and to pharmaceutical compositions. The present invention also relates to the use of the bispecific antibodies in the treatment of a tumor.

Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

Abstract: The present invention concerns the field of cancer immunotherapy, and in particular drugs with low toxicity which can overcome drug-resistance. The present invention concerns novel bispecific antibodies which have the capability of binding both the TRAIL tumor associated antigen and the T lymphocyte CD3. The invention further relates to compositions comprising the bispecific antibodies and a labelling agent, and to pharmaceutical compositions. The present invention also relates to the use of the bispecific antibodies in the treatment of a tumor.

Abstract: An isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen (PSMA) preferably in its native form on the surface of tumour cells. A conjugate of the antibody with an active ingredient and modified forms of the antigen-binding antibody fragment are also provided. The complete antibody and the antigen-recognising fragment thereof are used alone or conjugated for the treatment and the diagnosis of tumours or tissues associated to the tumour overexpressing the PSMA antigen, preferably prostatic neoplastic diseases.

Abstract: Antibody or fragment thereof, which specifically binds to folate receptor-alpha (FR?), wherein said antibody or fragment thereof comprises a light chain whose variable region comprises at least one of the following amino acid sequences: —RASESVSFLGINLIH (SEQ ID NO: 3), —QASNKDT (SEQ ID NO: 4), —LQSKNFPPYT (SEQ ID NO: 5), and wherein the constant region of said light chain is a kappa constant region.

Abstract: An isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen (PSMA) preferably in its native form on the surface of tumour cells. A conjugate of the antibody with an active ingredient and modified forms of the antigen-binding antibody fragment are also provided. The complete antibody and the antigen-recognising fragment thereof are used alone or conjugated for the treatment and the diagnosis of tumours or tissues associated to the tumour overexpressing the PSMA antigen, preferably prostatic neoplastic diseases.

Abstract: Antibody or fragment thereof, which specifically binds to folate receptor-alpha (FR?), wherein said antibody or fragment thereof comprises a light chain whose variable region comprises at least one of the following amino acid sequences: RASESVSFLGINLIH, (SEQ ID NO: 3) QASNKDT, (SEQ ID NO: 4) LQSKNFPPYT, (SEQ ID NO: 5) and wherein the constant region of said light chain is a kappa constant region.